BioNTech SE and Pfizer (PFE) recently received a positive recommendation from the European Medicines Agency for marketing ...

Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pfizer (PFE) stock in focus as company faces lawsuits over its alleged failure to warn about brain tumor risks linked to Depo ...

Pfizer (PFE) ended the recent trading session at $25.35, demonstrating a -1.17% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.14%.

Valley Wealth Managers Inc. grew its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 44.9% in the first quarter, ...

Pfizer Inc. (NYSE: PFE) is one of the 13 Best Large Cap Stocks to Buy Right Now. On July 10, Pfizer Inc. (NYSE:PFE) shared ...

Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and ...

This was the stock's third consecutive day of losses.

Pfizer Inc. closed 18.77% short of its 52-week high of $31.54, which the company achieved on July 30th.

PFE stock has seen a decline of 15% from levels of $35 in early January 2021 to around $30 now, vs. an increase of about 15% for the S&P 500 over this roughly 3-year period.